Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01321554 · ClinicalTrials.gov registry record · Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)
A Phase 3 study of Thyroid Cancer, sponsored by Eisai.
- Completed
- Registry status
- Phase 3
- Development phase
- 392
- Enrollment target
- 20
- Study locations
NCT01321554 is a Phase 3 study of Thyroid Cancer that has completed, run by Eisai. The registered enrollment target is 392 participants, above the 273-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (44% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT01321554, a Phase 3 study of Thyroid Cancer, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 392 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 study to compare the progression free survival, overall response rate (ORR) and safety of participants treated with lenvatinib 24 mg by continuous once daily oral dosing versus placebo. The study is conducted in 3 phases: a Prerandomization Phase (screening and baseline period), a Randomization Phase (double-blind treatment period), and an Extension Phase (Optional Open Label (OOL) Lenvatinib Treatment Period and a follow-up period).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Lenvatinib
Study Locations (20)
California
- Facility 1 - La Jolla
- Facility 1 - Los Gatos
- Facility 1 - Mission Viejo
- Facility 1 - Orange
- Facility 2 - Orange
- Facility 1 - Sacramento
- Facility 1 - Torrance
Michigan
- Facility 1 - Boston
- Facility 2 - Boston
- Facility 1 - Detroit
Florida
- Facility 1 - Orlando
- Facility 1 - Weston
Illinois
- Facility 1 - Chicago
- Facility 2 - Chicago
Arkansas
- Facility 1 - Little Rock
Colorado
- Facility 1 - Aurora
District of Columbia
- Facility 1 - Washington D.C.
Indiana
- Facility 1 - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 392 participants |
| Start Date | 2011-03-17 |
| Est. Completion | 2019-03-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01321554
The ClinicalTrials.gov registry entry for NCT01321554 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 392 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 273-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (44% higher). The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Thyroid Cancer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01321554 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Michigan, Florida.
Frequently Asked Questions
What is clinical trial NCT01321554 about?
NCT01321554 is a clinical study titled "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)". This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 study to compare the progression free survival, overall response rate (ORR) and safety of participants treated with lenvatinib 24 mg by continuous once daily oral dosing versus placebo. The study is conducted in 3 phases: a ...
What is the current status of trial NCT01321554?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 392 participants. The study started on 2011-03-17. Estimated completion is 2019-03-19.
What conditions does trial NCT01321554 study?
This clinical trial studies the following conditions: Thyroid Cancer.
What interventions are being tested in trial NCT01321554?
The interventions under investigation include: Placebo (DRUG), Lenvatinib (DRUG).
Who is sponsoring clinical trial NCT01321554?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01321554 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Artificial Tears to Prevent Nasolacrimal Duct Obstruction in Patients Treated With Radioactive Iodine for Thyroid Cancer
RECRUITING · Phase 3
-
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
COMPLETED · Phase 3
-
Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
RECRUITING · Phase 2
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.